$STE earnings report

Fiscal 2027 second quarter revenue increased 9%; constant currency organic revenue growth was 8%; as reported diluted EPS increased to $2.19; adjusted EPS per diluted share increased to $2.94. AlphAI read STERIS's Fiscal 2027 second quarter filing as solid. 2 quarters are on record below.

Fiscal 2027 second quarter

AlphAI · Earnings readSTE · Fiscal 2027 second quarter · ended September 30, 2026

Fiscal 2027 second quarter revenue increased 9%; constant currency organic revenue growth was 8%; as reported diluted EPS increased to $2.19; adjusted EPS per diluted share increased to $2.94.

✓Solid quarter

Revenue, segment operating income and both GAAP and adjusted diluted EPS increased from the prior-year quarter, led by 18% Life Sciences revenue growth. The full-year adjusted EPS outlook increased, while consolidated revenue growth expectations were unchanged and first-half operating cash flow and free cash flow declined.

Revenue
$1.59B
8.8 % y/y
Healthcare
$1.12B
8.6 % y/y
EPS · non-GAAP
$2.94
FY 2027, twelve months ended March 31, 2027 outlook
As reported revenue growth of 7-8% and constant currency organic revenue growth of 6-7%.

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Revenue, three months ended September 30, 2026GAAP$1.59B–8.8 %
Constant currency organic revenue growth, three months ended September 30, 2026non-GAAP8.1 %–8.1 %
Gross profit, three months ended September 30, 2026GAAP$710.8M––
Adjusted gross profit, three months ended September 30, 2026non-GAAP$719.6M––
Selling, general, and administrative expenses, three months ended September 30, 2026GAAP$366M––
Research and development expenses, three months ended September 30, 2026GAAP$31.5M––
Restructuring expenses, three months ended September 30, 2026GAAP$19.1M––
Total operating expenses, three months ended September 30, 2026GAAP$416.6M––
Income from operations, three months ended September 30, 2026GAAP$294.3M––
Adjusted income from operations, three months ended September 30, 2026non-GAAP$390.5M––
Net income, three months ended September 30, 2026GAAP$214.1M––
Net income attributable to shareholders, three months ended September 30, 2026GAAP$213.7M––
Adjusted net income attributable to shareholders, three months ended September 30, 2026non-GAAP$286.8M––
Diluted EPS, three months ended September 30, 2026GAAP$2.19––
Adjusted diluted EPS, three months ended September 30, 2026non-GAAP$2.94––
Income tax rate, three months ended September 30, 2026GAAP25.7 %––
Adjusted income tax rate, three months ended September 30, 2026non-GAAP25.3 %––
Revenue, six months ended September 30, 2026GAAP$3.08B–8.1 %
Constant currency organic revenue growth, six months ended September 30, 2026non-GAAP7.2 %–7.2 %
Gross profit, six months ended September 30, 2026GAAP$1.40B––
Income from operations, six months ended September 30, 2026GAAP$580.1M––
Adjusted income from operations, six months ended September 30, 2026non-GAAP$745.2M––
Net income attributable to shareholders, six months ended September 30, 2026GAAP$413.8M––
Diluted EPS, six months ended September 30, 2026GAAP$4.23––
Adjusted diluted EPS, six months ended September 30, 2026non-GAAP$5.53––
Net cash provided by operating activities, six months ended September 30, 2026GAAP$656.1M––
Free cash flow, six months ended September 30, 2026non-GAAP$492.5M––
Cash and cash equivalents, September 30, 2026GAAP$531.1M––
Short-term indebtedness, September 30, 2026GAAP$243.1M––
Long-term indebtedness, September 30, 2026GAAP$1.65B––
Total backlog, second quarter fiscal 2027other$548.9M––

Segments

SegmentRevenueq/qy/y
HealthcareService revenue increased 10%, consumables revenue grew 10%, and capital equipment revenue increased 4%. Constant currency organic revenue growth was 7%.$1.12B–8.6 %
Applied Sterilization Technologies (AST)Service revenue grew 5% and capital equipment revenue declined 21%. Constant currency organic revenue growth was 5%.$295.6M–5.0 %
Life SciencesCapital equipment revenue grew 53%, consumables revenue improved 9%, and service revenue grew 5%. Constant currency organic revenue growth was 18%.$170.6M–17.7 %

Amounts quoted below without a unit are in millions, as in the filing’s tables. Per-share figures are as printed.

FY 2027, twelve months ended March 31, 2027 outlook

  • RevenueAs reported revenue growth of 7-8% and constant currency organic revenue growth of 6-7%.
  • NoteAdjusted net income from continuing operations per diluted share $11.35 - $11.55
  • NoteNet income from continuing operations per diluted share $8.92 - $9.12
  • NoteCash flows from operating activities $1,250.0
  • NotePurchases of property, plant, equipment, and intangibles (450.0)
  • NoteFree Cash Flow $800.0
  • NoteHealthcare constant currency organic revenue growth 6-7%
  • NoteApplied Sterilization Technologies constant currency organic revenue growth 6-7%
  • NoteLife Sciences constant currency organic revenue growth 9-10%
  • NoteThe revised outlook includes the benefit of approximately $0.18 from tariff refunds received year-to-date.

Capital returns

  • Repurchases of ordinary shares were $(215.9) million for the six months ended September 30, 2026, compared with $(111.1) million for the six months ended September 30, 2025.
  • Cash dividends paid to ordinary shareholders were $(128.4) million for the six months ended September 30, 2026, compared with $(118.1) million for the six months ended September 30, 2025.
  • Cash dividends declared per ordinary share outstanding were $0.69 for the three months ended September 30, 2026, compared with $0.63 for the three months ended September 30, 2025.

What drove it

  • Second-quarter total revenue increased 9% to $1.6 billion, with constant currency organic revenue growth of 8%.
  • Healthcare operating income was $269.2 million, with improved volume and price partially offset by inflation, lower productivity and investments.
  • AST operating income was $132.1 million, as improved price was partially offset by inflation and increased depreciation.
  • Life Sciences operating income increased to $75.8 million, reflecting improvement in price, productivity, volume and favorable mix.
  • The pre-tax impact of tariff refunds on as reported second-quarter results was a benefit of approximately $20 million; gross tariff costs were flat with the prior year at $15 million for the quarter.
  • Corporate operating loss was $(86.7) million in the second quarter of fiscal 2027, compared with $(109.9) million in the prior-year quarter.

Concerns

  • First-half net cash provided by operating activities and free cash flow declined, driven primarily by a significantly lower contribution from working capital in fiscal 2027 compared with fiscal 2026.
  • AST capital equipment revenue declined 21% in the second quarter.
  • Second-quarter restructuring expenses were $19.1 million, compared with $2.2 million in the prior-year quarter.
  • The additional restructuring plan is expected to result in total charges of approximately $45 million, including approximately $10 million in cash expenditures and $35 million in non-cash charges.
  • The Company expects to discontinue disclosure of backlog beginning in fiscal 2028, as backlog has become a less meaningful indicator of future revenue trends across the business.

What to watch

  • Delivery against FY 2027 adjusted net income from continuing operations per diluted share outlook of $11.35 - $11.55.
  • Healthcare constant currency organic revenue growth outlook of 6-7%, AST outlook of 6-7%, and Life Sciences outlook of 9-10%.
  • The tariff-refund benefit of approximately $0.18 included in the revised outlook.
  • Execution of the additional targeted restructuring plan, which is expected to generate annualized savings of approximately $9 million, with a portion realized in fiscal 2028 and the full benefit realized in subsequent fiscal years.
  • Revised fiscal 2027 outlook inclusive of the proposed Xodus Medical acquisition after closing.
  • Cash flows from operating activities outlook of $1,250.0 and Free Cash Flow outlook of $800.0.

Balance sheet and cash flow

  • Cash and cash equivalents were $531.1 million at September 30, 2026, compared with $439.6 million at March 31, 2026.
  • Short-term indebtedness was $243.1 million and long-term indebtedness was $1,650.3 million at September 30, 2026.
  • Net cash provided by operating activities was $656.1 million for the six months ended September 30, 2026, compared with $707.8 million in the prior-year period.
  • Purchases of property, plant, equipment, and intangibles were $(163.6) million for the six months ended September 30, 2026, compared with $(180.1) million in the prior-year period.
  • Free cash flow was $492.5 million for the six months ended September 30, 2026, compared with $527.7 million in the prior-year period.

Analysis

STERIS reported second-quarter revenue of $1,588.6 million, compared with $1,460.3 million in the prior-year quarter. The company reported 8.8 % U.S. GAAP revenue growth and 8.1 % constant currency organic revenue growth. Recurring revenue was $1,268.0 million and capital equipment revenue was $320.6 million. GAAP income from operations rose to $294.3 million from $265.8 million, while adjusted income from operations increased to $390.5 million from $337.1 million. GAAP diluted EPS was $2.19 and adjusted diluted EPS was $2.94, compared with $1.94 and $2.47, respectively.

All three operating segments increased revenue. Healthcare generated $1,122.4 million of revenue and $269.2 million of segment operating income, with service and consumables each growing 10%. AST revenue was $295.6 million and segment operating income was $132.1 million. Its service revenue grew 5%, but capital equipment revenue declined 21%. Life Sciences was the principal growth contributor, with revenue of $170.6 million, 17.7 % U.S. GAAP growth, 18.1 % constant currency organic growth, and segment operating income of $75.8 million. Its capital equipment revenue grew 53%.

The company cited improved volume and price in Healthcare, price improvement in AST, and price, productivity, volume and favorable mix in Life Sciences as operating-income drivers. Second-quarter GAAP results also received a pre-tax benefit of approximately $20 million from tariff refunds, while gross tariff costs were flat with the prior year at $15 million. Restructuring expenses were $19.1 million in the quarter. A separate targeted plan approved during the quarter is expected to generate annualized savings of approximately $9 million, but carries anticipated charges of approximately $45 million.

Cash conversion was weaker through the first half. Net cash provided by operating activities was $656.1 million and free cash flow was $492.5 million, compared with $707.8 million and $527.7 million in the prior-year period. The company attributed the declines primarily to a significantly lower working-capital contribution, partially offset by higher net income. It repurchased $(215.9) million of ordinary shares and paid $(128.4) million of cash dividends during the six-month period. Cash and cash equivalents were $531.1 million at September 30, 2026.

The FY 2027 consolidated revenue-growth outlook was unchanged at 7-8% as reported and 6-7% constant currency organic. Adjusted net income from continuing operations per diluted share guidance increased to $11.35 - $11.55 from prior expectations of $11.10 to $11.30, including approximately $0.18 from tariff refunds received year-to-date. Segment outlook changed materially beneath the unchanged consolidated revenue framework: AST constant currency organic growth is now 6-7% versus prior outlook of 7-8%, while Life Sciences is now 9-10% versus 6-7%; Healthcare remains 6-7%.

Management, verbatim

We are pleased with our second quarter performance.

Dan Carestio, President and CEO of STERIS

Life Sciences delivered particularly strong performance in the quarter, giving us confidence to raise our expectations for the segment for the full year.

Dan Carestio, President and CEO of STERIS

Fiscal 2027 is shaping up to be another record year for STERIS, supported by solid underlying demand and excellent execution from our commercial teams.

Dan Carestio, President and CEO of STERIS

Not in the filing

stated, not guessed
  • No gross margin percentage was reported for the second quarter or six-month period.
  • No prior-quarter figures were reported for the income statement, segment revenue, segment operating income, EPS, operating cash flow, or free cash flow metrics.
  • No forward gross margin, operating expenses, or tax rate guidance was reported.
  • No total debt line item was reported; short-term indebtedness and long-term indebtedness were reported separately.
  • The previous outlook covered the full fiscal 2027 year only, and this quarterly release reports the second quarter, so there is no guidance for this period to compare.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Fiscal 2027 first quarter

AlphAI · Earnings readSTE · Fiscal 2027 first quarter · ended June 30, 2026

Fiscal 2027 first quarter revenue increased 7%; constant currency organic revenue growth was 6%; as reported diluted EPS increased to $2.04; adjusted EPS per diluted share increased to $2.59.

✓Solid quarter

Revenue, reported earnings, adjusted earnings and all three reported segments increased year over year, supported by stable underlying demand, Healthcare share gains and pricing. Cash flow declined year over year, while increased capital expenditure expectations and a restructuring program reduced expected free cash flow.

Revenue
$1.5B
increased 7% y/y
Healthcare
$1.05B
grew 8% y/y
EPS · GAAP
$2.04
increased y/y
Fiscal 2027 outlook
as reported revenue growth of 7-8% and constant currency organic revenue growth of 6-7%

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Total revenueGAAP$1.5B–increased 7%
Constant currency organic revenue growthnon-GAAP6%––
Net incomeGAAP$200.1M––
Diluted EPSGAAP$2.04 per diluted share–increased
Adjusted net incomenon-GAAP$253.4M––
Adjusted EPSnon-GAAP$2.59 per diluted share–increased
Healthcare operating incomeGAAP$260.2M––
Applied Sterilization Technologies operating incomeGAAP$142.9M––
Life Sciences operating incomeGAAP$61.8M–increased
Net cash provided by operationsGAAP$367.1M––
Free cash flownon-GAAP$279.6M––

Segments

SegmentRevenueq/qy/y
Healthcare10% improvement in service revenue, 9% growth in consumable revenue, and a 1% increase in capital equipment revenue; constant currency organic revenue growth was 6%.$1.05B–grew 8%
Applied Sterilization Technologies (AST)6% growth in service revenue and a 13% decline in capital equipment revenue; constant currency organic revenue growth was 5%.$297.6M–increased 6% as reported
Life Sciences17% growth in capital equipment revenue, 8% improvement in consumable revenue, and 2% growth in service revenue; constant currency organic revenue increased 8%.$146.7M–increased 9%

Fiscal 2027 outlook

  • Revenueas reported revenue growth of 7-8% and constant currency organic revenue growth of 6-7%
  • NoteAdjusted earnings per diluted share are anticipated to be in the range of $11.10 to $11.30.
  • NoteCapital expenditures are now anticipated to be approximately $450 million compared with prior expectations of $375 million.
  • NoteFree cash flow is now expected to be approximately $800 million compared with prior expectations of $850 million.
  • NoteTotal pre-tax restructuring charges of approximately $55 million to $70 million, consisting of approximately $40 million to $50 million of cash expenditures and approximately $15 million to $20 million of non-cash charges.
  • NoteCompletion of the restructuring plan is anticipated to occur during fiscal 2030.

What drove it

  • Management cited stable underlying demand.
  • Healthcare performance was driven by share gains in consumables and services, with solid order growth for capital equipment.
  • Healthcare operating income increased primarily due to improved volume, price, productivity and favorable mix, partly offset by inflation and increased tariff costs.
  • AST operating income increased primarily on improved price, partly offset by increased depreciation and labor.
  • Life Sciences operating income increased on price and volume, partly offset by inflation and lower productivity.
  • The decline in operating cash flow and free cash flow was primarily driven by a significantly lower contribution from working capital, partly offset by higher net income.

Concerns

  • Healthcare operating income faced inflation and increased tariff costs.
  • AST capital equipment revenue declined 13%.
  • Life Sciences productivity was lower.
  • Net cash provided by operations and free cash flow declined from the prior-year period.
  • Capital expenditures are now anticipated to be approximately $450 million compared with prior expectations of $375 million.
  • The Company expects restructuring charges associated with consolidating formulated chemistries manufacturing and distribution to a new Center of Excellence in North Carolina.

What to watch

  • Execution of the formulated chemistries Center of Excellence in North Carolina and the anticipated closure of facilities in St. Louis, Missouri, and Plymouth, Minnesota.
  • Whether Healthcare service, consumable and capital-equipment growth continues.
  • Whether AST capital equipment revenue improves following the reported 13% decline.
  • Working-capital contribution and progress toward expected free cash flow of approximately $800 million.
  • Inflation, increased tariff costs, labor costs and Life Sciences productivity.

Balance sheet and cash flow

  • Net cash provided by operations was $367.1 million, compared with $420.0 million in the first quarter of fiscal 2026.
  • Free cash flow was $279.6 million compared with $326.5 million in the prior year period.

Analysis

STERIS reported a solid fiscal 2027 first quarter. Total revenue increased 7% to $1.5 billion, and constant currency organic revenue growth was 6%. Reported net income was $200.1 million, or $2.04 per diluted share, compared with $177.4 million, or $1.79 per diluted share, in the prior-year quarter. Adjusted net income was $253.4 million, or $2.59 per diluted share, compared with $231.2 million, or $2.34 per diluted share.

All three reported segments delivered revenue growth. Healthcare revenue grew 8% to $1.05 billion, with services, consumables and capital equipment all growing. Management attributed the segment's operating-income improvement to volume, price, productivity and favorable mix, although inflation and increased tariff costs were offsets. AST revenue increased 6% to $297.6 million, supported by service revenue, while capital equipment revenue declined 13%. Life Sciences revenue increased 9% to $146.7 million, led by capital equipment revenue growth of 17%.

Segment operating income increased across Healthcare, AST and Life Sciences. Pricing was a driver in AST and Life Sciences, while Healthcare also benefited from volume, productivity and mix. The release identifies pressures from inflation, tariffs, labor, increased depreciation and lower Life Sciences productivity. These cost and productivity factors, together with the AST capital-equipment decline, are the main operating items requiring attention in subsequent periods.

Cash conversion was weaker year over year. Net cash provided by operations was $367.1 million compared with $420.0 million, and free cash flow was $279.6 million compared with $326.5 million. The Company attributed the decrease primarily to a significantly lower working-capital contribution, partially offset by higher net income. No capital-return activity, cash balance or debt balance was reported in the provided text.

The Company reiterated fiscal 2027 revenue-growth and adjusted-EPS expectations. It now anticipates capital expenditures of approximately $450 million compared with prior expectations of $375 million, and free cash flow of approximately $800 million compared with prior expectations of $850 million. STERIS also announced a targeted restructuring plan tied to a North Carolina formulated chemistries Center of Excellence, with expected total pre-tax restructuring charges of approximately $55 million to $70 million and completion anticipated during fiscal 2030.

Management, verbatim

We are pleased with our performance in the first quarter.

Dan Carestio, President and CEO of STERIS

Our first quarter results reflected stable underlying demand, while our commercial teams continue to drive meaningful growth within the Healthcare segment.

Dan Carestio, President and CEO of STERIS

Our revenue and earnings expectations for the year are unchanged, as the strength of our portfolio continues to enable us to help our Customers navigate a complex operating environment.

Dan Carestio, President and CEO of STERIS

Not in the filing

stated, not guessed
  • Total gross profit and gross margin
  • Total operating income and operating margin
  • Adjusted operating income and adjusted gross profit
  • Income-tax expense and tax rate
  • Prior-quarter comparisons for all reported metrics
  • Total Company revenue by product category
  • Balance-sheet cash balance
  • Debt balance
  • Share repurchases
  • Dividends
  • Capital-return amounts
  • GAAP EPS guidance
  • Gross-margin guidance
  • Operating-expense guidance
  • Tax-rate guidance
  • Previous-release outlook for formal reported-results-versus-prior-guidance comparisons

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Questions about STE earnings dates

When is STERIS's next earnings date?
AlphAI has no date for STE yet. We do not publish estimates, so this page shows a date the day we have one.
Why is there sometimes no date?
AlphAI leaves out estimates. Many sites fill the gap by adding about 91 days to the last report, but that arithmetic is a guess, and a wrong date costs a reader more than a missing one, so we show nothing until a date is set, and a company can still move it. Every quarter already on this page is read straight from the SEC filing: an 8-K item 2.02 for US filers, a 6-K earnings release for foreign private issuers.